Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Immunotherapy

Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRongna WangTGTianhui GuoQWQi Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows IC-ICCRT-IO significantly improves progression-free and overall survival in patients with unresectable ESCC, indicating enhanced treatment efficacy.

Key Points

  • IC-ICCRT-IO significantly improved progression-free survival compared to CT-CCRT, indicating better treatment efficacy.
  • The median progression-free survival not reached for IC-ICCRT-IO, with 12-month rates of 96.6% versus 80.5% for CT-CCRT.
  • Patients receiving IC-ICCRT-IO had a higher objective response rate of 88.9% compared to 48.1%, reflecting treatment effectiveness.
  • Grade ≥3 adverse events were comparable between both treatments, indicating that IC-ICCRT-IO is safe for patients with unresectable ESCC.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c23caeb210217d64789c7fhttps://doi.org/10.1097/cji.0000000000000578
View Full Paper
Ask AI
Bookmark
Share